Tesamorelin |
|
| Size/Unit | 2 mg/vial
5 mg/vial 10 mg/vial
|
| Quantity/Unit | 1 kit |
| Physical Appearance | White |
| Peptide Purity | 98.4% |
| Molecular Formula | C221H366N72O67S |
| Molecular Mass | |
| CAS NO. |
106612-94-6 |
| Storage Guidelines |
Tesamorelin will remain stable at room temperature for up to 90 days. Ideally it should be stored in a freezer at or below -9C.Tesamorelin should be refrigerated after reconstitution. |
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
Tesamorelin 2mg
Product Name: Tesamorelin
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.77794
Synonyms: Hex-hGRF, ThGRF(1-44), TH-9507, (Hexenoyl trans-3)-hGRF(1-44)-NH2
Sequence (Three-Letter Code): trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Tesamorelin, (formerly known as TH9507), is a type of peptide called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete growth hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.
Tesamorelin Boosts Cognition in Elderly
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
A peptide that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of growth hormone releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
In animal studies, GHRH administration improved biomarkers of brain function as well as performance on cognition tests. And a 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously.
Mean participant age was 66 to 70 among the four groups. Scores on the Mini-Mental State Examination averaged 29 for the normal participants and 28 for those with mild impairments. Normal and impaired participants differed more at baseline on a test of story recall, with mean scores of 54 and 44, respectively. Tesamorelin appeared to have a protective effect relative to placebo among the cognitively impaired patients on this measure. At the final evaluation, scores declined an average of five points with placebo, whereas those assigned to tesamorelin had a mean decline of less than one point (P
Fat Loss and the Tesamorelin Peptide
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes HGH production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).
related products:
GHRP-6 5mg
Growth Hormone Releasing Peptide 2
Peptide Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Formula: C45H55N9O6 Molar Mass: 817.9 g/mol CAS Number: 158861-67-7
price is base on per vial
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
The hexipeptide GHRP – 6 is a secretagogue peptide that has a molecular formula of C46H56N12O6and a molecular weight of 873.014. Its structure is comprised of six amino acids. The name of the peptide itself is an acronym that stands for Growth Hormone Releasing Peptide.
GHRP – 6 and the Pituitary Gland
Scientific study that has been based on animal test subjects has determined that the way in which GHRP 6 has been shown to function chiefly ties into its relationship with the pituitary gland; the tiny, pea-sized gland that is located at the bottom of the hypothalamus at the base of the brain. In essence, this gland is charged with the regulation and control of a host of different processes that are tied to the endocrine system. Some of these processes include metabolism, thyroid gland functionality, temperature regulation, internal water regulation, pain relief, and growth. GHRP – 6’s overall functionality is such that it inhibits the pituitary gland from blocking the production of secretions that directly tie to these regulatory processes. This then allows for the animal test subject to have the ability experience a more efficient means of achieving a level of homeostasis in regards to these regulatory processes.
GHRP – 6 and the Stomach
It has also been determined by scientific study based on animal test subjects that GHRP – 6’s overall functionality can be linked to the production of ghrelin. In essence, ghrelin is an amino acid that is primarily produced by the cells that line the stomach, although it has been noted that it can also be secreted by the epsilon cells that are found in the pancreas. The expression of this particular secretion serves to stimulate the sensation of hunger; this allows it to act as a counterbalance to amino acid leptin, whose secretion stimulates the sensation of feeling full. Studies have indicated that GHRP – 6’s functionality allows for a greater level of ghrelin to be produced. This extra level of production prolongs the amount of which an animal test subject can experience hunger. This in turn enables the test subject to intake a greater amount of food which can then be used as fuel for the pituitary gland’s elevated ability to secrete endocrine system-related expressions.
GHRP – 6 and the Liver
Further scientific study that has been based on animal test subjects has determined that GHRP – 6’s abilities have a connection with the liver; specifically, with a liver-based secretion known as Insulin-like Growth Factor-1, or IGF-1. This secretion has been shown to be highly reactive in nature, meaning that its expression has been tied to the growth and repair of muscle and tissue growth. Studies have indicated that GHRP – 6 has the capacity to influence an elevated production amount of this particular secretion, thus allowing an animal test subject a more efficient rate in achieving homeostasis on a muscular and skeletal tissue level.
GHRP – 6 and the Central Nervous System
It has also been determined through scientific study based on animal test subjects that the presence of GHRP – 6 aids in the activation of intracellular signaling pathways along the central nervous system; these pathways are ones that are used by various secretions that are tied to the pituitary gland. Additionally, it has been shown that it has the ability to promote a greater level of protein expression in terms of overall cellular survival. These functions have led to the determination that it could be a prime ally in the guarding against cell loss and functionality in the aftermath of a hypoxic-ischemic brain injury, such as:
- Stroke
- Angina Pectoris caused by cardiac arrest
- Angina Pectoris caused by respiratory arrest
Various Elevated Processes
Because of the way in which GHRP 6 has been shown to function, scientific study that has been based on animal test subjects has been able to determine that its presence can be responsible for several elevated processes. These processes have been thought to include an increase in muscle growth, a decrease in body fat, an elevation in muscle and tissue repair, an expedited rate of recovery from injury, a boost in bone density, increased immune system efficiency, and a boost in connective tissue and joint strengthening.
Strictly for Controlled Environments
It should be noted that any findings or observations that relate to GHRP – 6 and its overall functionality should exclusively be done within a strictly controlled environment, such as a medical research facility or a laboratory. The reason for this is due to the fact that the peptide and the study its operational is currently just fit for scientific study on animal test subjects. As such, it should be noted that research that has been derived regarding GHRP – 6 is due to scientific tests conducted in a controlled environment only.
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular formula: C152H252N44O42
Molar Mass: 3368.7
Synonyms: Mod GRF 1-29, CJC-1295 no DAC
Modified Growth Releasing Factor aminos 1-29, usually referred to as Modified GRF (1-29) or “ModGRF(1-29),” also known as CJC-1295 without DAC, is a synthetic analog of the endogenous peptide signaling hormone Growth Hormone Releasing Hormone (GHRH). Endogenously produced GHRH has 44 amino acids in its chain structure. A truncated synthetic form of GHRH called Sermorelin or GRF 1-29 has 29 amino acids; Modified GRF (1-29) is further changed in that it has four substituted aminos in its chain that serve the purposes of preventing degradation and oxidation in manufacture and transport as well as in vivo, while also increasing binding affinity to the GHRH receptors.
Modified GRF (1-29) is not CJC-1293 nor should it be referred to as such. Modified GRF (1-29) is identical to the portion of CJC-1295 DAC that is not bound to MPA, minus the lysine. The presence of lysine in a literal “CJC without DAC” in the absence of MPA would have the opposite effect of DAC: it would drastically reduce the active life of the peptide to that of Sermorelin. Modified GRF (1-29) is the same as CJC-1295 with out DAC.
Tetrasubstitued GRF (1-29)
Modified GRF (1-29) is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation.
CJC-1295 DAC vs. CJC-1295 No DAC
CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.